FeesSafety
Pluang+

Azimut begins updated mineral resource estimate for Patwon Gold Deposit after 2026 drilling in Québec.

Market News
03 Nov 2026, 13:30 WIB
GlobeNewsWire
View Source
Bullish
Azimut begins updated mineral resource estimate for Patwon Gold Deposit after 2026 drilling in Québec.

Azimut Exploration Inc. has started a new NI 43-101 mineral resource estimate for the Patwon Gold Deposit in Québec following its 2026 diamond drilling program, which showed promising gold intercepts outside the current resource shell. The updated estimate will incorporate recent drill results and reflect higher gold prices, with completion expected by the end of 2026. The company plans further drilling to expand the deposit and is assessing copper-gold targets on its Elmer Property, which now covers a 43-kilometre strike length. Several parties have shown interest in the project, and Azimut continues to advance other key projects in the region.

Azimut's new mineral resource estimate for the Patwon Gold Deposit is underway, with completion expected by the end of 2026. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Nov 03, 2026 17:51 WIB: out of 83 priced US stocks, 22 rose and 57 fell. Notable movers include TECK at USD 61.00 with a -2.77% change and a typical hold time of 22 days, EXK at USD 7.03 down 2.77% with 38% sell and 62% buy order activity, and HYMC at USD 15.88 down 2.76% with a typical hold time of 11 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App